ATE506061T1 - Zusammensetzungen und verfahren zur behandlung, kontrolle, verminderung, verbesserung bzw. prävention von allergien - Google Patents

Zusammensetzungen und verfahren zur behandlung, kontrolle, verminderung, verbesserung bzw. prävention von allergien

Info

Publication number
ATE506061T1
ATE506061T1 AT07841298T AT07841298T ATE506061T1 AT E506061 T1 ATE506061 T1 AT E506061T1 AT 07841298 T AT07841298 T AT 07841298T AT 07841298 T AT07841298 T AT 07841298T AT E506061 T1 ATE506061 T1 AT E506061T1
Authority
AT
Austria
Prior art keywords
allergies
prevention
compositions
improvement
reduction
Prior art date
Application number
AT07841298T
Other languages
English (en)
Inventor
Brian Rohrs
Timothy Comstock
Zhenze Hu
Gary Phillips
Original Assignee
Bausch & Lomb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bausch & Lomb filed Critical Bausch & Lomb
Application granted granted Critical
Publication of ATE506061T1 publication Critical patent/ATE506061T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT07841298T 2006-09-11 2007-08-24 Zusammensetzungen und verfahren zur behandlung, kontrolle, verminderung, verbesserung bzw. prävention von allergien ATE506061T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84362906P 2006-09-11 2006-09-11
PCT/US2007/076701 WO2008033655A2 (en) 2006-09-11 2007-08-24 Compositions and methods for treating, controlling, reducing, ameliorating, or preventing allergy

Publications (1)

Publication Number Publication Date
ATE506061T1 true ATE506061T1 (de) 2011-05-15

Family

ID=38819731

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07841298T ATE506061T1 (de) 2006-09-11 2007-08-24 Zusammensetzungen und verfahren zur behandlung, kontrolle, verminderung, verbesserung bzw. prävention von allergien

Country Status (17)

Country Link
US (1) US20080064721A1 (de)
EP (1) EP2061444B1 (de)
JP (1) JP2010502723A (de)
KR (1) KR20090050076A (de)
CN (1) CN101553214B (de)
AT (1) ATE506061T1 (de)
AU (1) AU2007297054A1 (de)
BR (1) BRPI0716625A2 (de)
CA (1) CA2661197C (de)
DE (1) DE602007014067D1 (de)
DK (1) DK2061444T3 (de)
ES (1) ES2361585T3 (de)
MX (1) MX2009002544A (de)
PL (1) PL2061444T3 (de)
PT (1) PT2061444E (de)
TW (1) TWI344467B (de)
WO (1) WO2008033655A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090087443A1 (en) * 2007-09-27 2009-04-02 Bartels Stephen P Pharmacological Adjunctive Treatment Associated with Glaucoma Filtration Surgery
ES2402321T3 (es) * 2007-11-05 2013-04-30 Bausch & Lomb Incorporated Materiales inmiscibles en agua como vehículos para el suministro de fármacos
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8263581B2 (en) 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
WO2013126156A1 (en) * 2012-02-22 2013-08-29 Bausch & Lomb Incorporated Nitric oxide donating selective glucocorticoid receptor agonist compounds and ophthalmic compositions
AU2020211303A1 (en) 2019-01-22 2021-07-15 Akribes Biomedical Gmbh Selective Glucocorticoid Receptor Modifiers for treating impaired skin wound healing

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614611A (en) * 1987-12-31 1997-03-25 Tanox Biosystems, Inc. Humanized monoclonal antibodies binding to IgE-bearing B cells but not basophils
US5449760A (en) * 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
WO1995019181A1 (en) * 1994-01-18 1995-07-20 Genentech, Inc. A METHOD OF TREATMENT OF PARASITIC INFECTION USING IgE ANTAGONISTS
US6051576A (en) * 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5902598A (en) * 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
US6242196B1 (en) 1997-12-11 2001-06-05 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumor cell growth
AU4713499A (en) 1998-06-27 2000-01-17 Photogenesis, Inc. Ophthalmic uses of ppargamma agonists and ppargamma antagonists
WO2001035963A1 (en) * 1999-11-18 2001-05-25 Alcon Universal Ltd. Use of h1 antagonist and a safe steroid to treat eye conditions
US6726918B1 (en) * 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
WO2003059899A1 (en) * 2002-01-14 2003-07-24 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof
UA80120C2 (en) * 2002-03-26 2007-08-27 Boehringer Ingelheim Pharma Glucocorticoid mimetics, pharmaceutical composition based thereon
AU2003230700A1 (en) * 2002-03-26 2003-10-13 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US6897224B2 (en) * 2002-04-02 2005-05-24 Schering Ag Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors
US7074806B2 (en) * 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
MXPA05000345A (es) * 2002-07-08 2005-03-31 Pfizer Prod Inc Moduladores del receptor de glucocorticoides.
US7579469B2 (en) * 2003-01-03 2009-08-25 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US20040224992A1 (en) * 2003-02-27 2004-11-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2004097410A1 (en) * 2003-04-30 2004-11-11 Pfizer Products Inc. Screening methods for cataractogenic risk
UY28526A1 (es) * 2003-09-24 2005-04-29 Boehringer Ingelheim Pharma Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
US7795272B2 (en) * 2004-03-13 2010-09-14 Boehringer Ingelheim Pharmaceutical, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
JP2007530541A (ja) * 2004-03-22 2007-11-01 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド グルココルチコイドミメチックスとしてのα−トリフルオロメチルアルコール又はアミン
DE102004055633A1 (de) * 2004-11-12 2006-05-18 Schering Ag 5-substituierte Chinolin- und Isochinolin-Derivate, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
US7417056B2 (en) * 2004-11-12 2008-08-26 Schering Ag 5-substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents
DE102004055030B4 (de) * 2004-11-15 2009-09-10 Knorr-Bremse Systeme für Nutzfahrzeuge GmbH Vorrichtung zur Beaufschlagung eines Kolbenstellers mit Druck
JP2008535884A (ja) * 2005-04-14 2008-09-04 グラクソ グループ リミテッド グルココルチコイド受容体リガンドとしてのインダゾール

Also Published As

Publication number Publication date
CA2661197C (en) 2012-01-03
DE602007014067D1 (de) 2011-06-01
CN101553214A (zh) 2009-10-07
CN101553214B (zh) 2012-12-26
ES2361585T3 (es) 2011-06-20
KR20090050076A (ko) 2009-05-19
WO2008033655A2 (en) 2008-03-20
TWI344467B (en) 2011-07-01
TW200819442A (en) 2008-05-01
BRPI0716625A2 (pt) 2013-10-08
JP2010502723A (ja) 2010-01-28
PL2061444T3 (pl) 2011-09-30
EP2061444B1 (de) 2011-04-20
AU2007297054A1 (en) 2008-03-20
US20080064721A1 (en) 2008-03-13
EP2061444A2 (de) 2009-05-27
DK2061444T3 (da) 2011-06-27
WO2008033655A3 (en) 2008-10-02
PT2061444E (pt) 2011-07-08
CA2661197A1 (en) 2008-03-20
MX2009002544A (es) 2009-03-20

Similar Documents

Publication Publication Date Title
ATE506061T1 (de) Zusammensetzungen und verfahren zur behandlung, kontrolle, verminderung, verbesserung bzw. prävention von allergien
MXPA05013224A (es) Piridinilcarbamatos como inhibidores de lipasa sensible a hormonas.
AU2003256755A1 (en) Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
MXPA04002167A (es) Inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes.
UA94909C2 (ru) Фармацевтическая композиция нейроактивного стероида и ее применение
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
TW200733976A (en) Method for the treatment of cognitive dysfunction
TW200637618A (en) Compositions and methods for treating conditions of the nail unit
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
TW200509937A (en) Novel compounds and their use in therapy
WO2006078424A3 (en) Polyherbal compositions and methods for treating viral infections
WO2007138466A3 (en) Pharmaceutical compositions comprising meloxicam and tramadol combination
WO2007143557A3 (en) Compounds and methods for treating mammalian gastrointestinal parasitic infections
CA2632207C (en) Use of calcitonin for the treatment of ra
BRPI0412919A (pt) combinação de antagonista de mglur2 e inibidor de ache para o tratamento de distúrbios neurológicos crÈnicos e/ou agudos
BRPI0411864A (pt) combinação de inibidores de src quinase e agentes quimioterápicos para o tratamento de doenças proliferativas
WO2004043456A8 (en) Cholesterol absorption inhibitors for the treatment of demyelination
EA200800766A1 (ru) Ингибиторы pi3k для лечения эндометриоза
MX2022009197A (es) Metodos de tratamiento para deficiencia de alfa-1 antitripsina.
DE60234919D1 (de) 3, 7 oder 3 und 7 thia- oder oxaprostansäure derivate als mittel zur senkung des augeninnendrucks
WO2006113718A3 (en) Compositions for the treatment of neoplasms
MX2009002228A (es) Composiciones y metodos para tratar o prevenir glaucoma o el avance del mismo.
WO2006060196A3 (en) Use of rottlerin and its derivatives as activators of bk channel for therapy of hypertension and related disorders
TW200738232A (en) Use of vanilloid receptor-1 antagonists for the prevention and treatment of glaucoma
EA201992826A1 (ru) 15бета-[3-пропанамидо]-замещенные эстра-1,3,5(10)-триен-17-оны и их 17-оксимы для применения в ингибировании 17бета-гидроксистероиддегидрогеназ

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2061444

Country of ref document: EP